ClinicalTrials.gg
RecruitingNCT05735717Updated Apr 6, 2026

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

A Phase 2 interventional study of Fludarabine and Busulfan in Hematologic Malignancy, Acute Leukemia and Remission, sponsored by Masonic Cancer Center, University of Minnesota. Recruiting at 1 site in United States. Open to participants aged Up to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Masonic Cancer Center, University of Minnesota · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
Up to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies testing fludarabine in Hematologic Neoplasms — 11 open to participants now, 12 under way, none of them phase 3. fludarabine · Hematologic Neoplasms.

Planned enrollment
9th of 41
70 · median 32
Started
2023
with 2 others
Phase 2
20 of 41
5 open now
Primary completion
2027-11
later than 2 of 11 live
Registered
32nd of 41
by date

Among the 41 studies testing fludarabine in Hematologic Neoplasms, this one is the 9th largest by planned enrollment, is one of 3 that started in 2023, is one of 20 in phase 2, reaches primary completion later than 2 of the 11 other live ones, and was the 32nd registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

11 of the 41 studies testing fludarabine in Hematologic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About fludarabine

fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: Up to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing fludarabine in Hematologic Neoplasms, or all of them as a file.
02

Study summary

This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety/feasibility study of the investigational procedure/product.

03

Conditions studied

  • Hematologic Malignancy
  • Acute Leukemia
  • Remission
  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • AML
  • TP53
  • Intrachromosomal Amplification of Chromosome 21
  • Cytogenetic Abnormality
  • CNS Leukemia
  • Minimal Residual Disease
  • Myelodysplasia
  • Juvenile Myelomonocytic Leukemia
  • Somatic Mutation
  • PTPN11 Gene Mutation
  • N-RAS Gene Amplification
  • Neurofibromatosis 1
  • NF1 Mutation
  • CBL Gene Mutation
  • Monosomy 7
  • Chromosome Abnormality
  • Fetal Hemoglobin
  • Lymphoblastic Lymphoma
  • High Grade Non-Hodgkin's Lymphoma, Adult

Keywords

  • Bu
  • Flu
  • G-CSF
  • GFSR
  • aGVHD
  • HCT
  • MAC
  • Mel
  • PBSCT
  • PTLD
  • RECIST
  • TCR
04

Who can participate

Ages eligible
Up to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological confirmation of hematological
  • Acute leukemias
  • Acute Myeloid Leukemia (AML) and related precursor neoplasms
  • Favorable risk AML is defined as having one of the following:
  • Acute lymphoblastic leukemia (ALL)/lymphoma
  • Myelodysplasia (MDS) IPSS INT-2 or High Risk (i.e. RAEB, RAEBt) or Anemia with severe pancytopenia, transfusion dependence, or high risk cytogenetics or molecular features.
  • Age 60 years of age or younger at the time of consent
  • performance status ≥ 70% or Lansky play score 50% for ≤16 years of age.
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding.
  • Active uncontrolled infection within 1 week of starting preparative therapy
  • Known seropositive for or known active or C infection with detectable viral load by PCR.
  • Any prior or allogeneic transplant
  • CML blast crisis
  • Active central nervous system
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Arm 1A: Fludarabine (flu), Total Body Irradiation (TBI), Flu/TBI Regimen, Closed to Accrual

    Patients will be treated on the most medically appropriate regimen with a preference for Flu/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.

    Drug: Fludarabine · Drug: Rituximab · Drug: Levetiracetam · Biological: Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells

  • Experimental
    Arm 2A: Fludarabine (flu), Busulfan (bu), Flu/Bu Regimen, Closed to Accrual

    Patients will be treated on the most medically appropriate regimen with a preference for Flu/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.

    Drug: Fludarabine · Drug: Busulfan · Drug: Rituximab · Drug: Levetiracetam

  • Experimental
    Arm 3A: Fludarabine (flu), Busulfan (bu), Melphalan (Mel) Regimen for Pediatric Patients Only

    Flu/Bu/Mel will the preference for patients with JMML or infants with leukemia. , Closed to Accrual

    Drug: Fludarabine · Drug: Busulfan · Drug: Melphalan · Drug: Rituximab · Drug: Levetiracetam

  • Experimental
    Arm 1B: ATG, Fludarabine (flu), Total Body Irradiation (TBI), Flu/TBI Regimen

    Patients will be treated on the most medically appropriate regimen with a preference for ATG/Flu/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.

    Drug: Fludarabine · Drug: Rituximab · Drug: Levetiracetam · Drug: Thymoglobulin

  • Experimental
    Arm 2B: ATG, Fludarabine (flu), Busulfan (bu), Flu/Bu Regimen

    Patients will be treated on the most medically appropriate regimen with a preference for ATG/Flu/BU/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.

    Drug: Fludarabine · Drug: Busulfan · Drug: Rituximab · Drug: Levetiracetam · Drug: Thymoglobulin

  • Experimental
    Arm 3B: ATG, Fludarabine (flu), Busulfan (bu), Melphalan (Mel) Regimen for Pediatric Patients Only

    ATG/Flu/Bu/Mel will the preference for patients with JMML or infants with leukemia.

    Drug: Fludarabine · Drug: Busulfan · Drug: Melphalan · Drug: Rituximab · Drug: Levetiracetam · Drug: Thymoglobulin

  • Experimental
    Arm 4B: ATG, Busulfan (BU), Cyclophosphamide (CY)

    Patients will be treated on the most medically appropriate regimen with a preference for ATG/BU/CY Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.

    Drug: Busulfan · Drug: Rituximab · Drug: Levetiracetam · Drug: Thymoglobulin · Drug: Cyclophosphamide

  • Experimental
    Arm 5B: ATG, Cyclophosphamide (CY), Total Body Irradiation (TBI)

    Patients will be treated on the most medically appropriate regimen with a preference for ATG/CY/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.

    Drug: Rituximab · Drug: Levetiracetam · Drug: Thymoglobulin · Drug: Cyclophosphamide

Interventions

  • Fludarabine 25mg/m2 IV on days -8 to -6 or days -4 to -2. 40mg/m2 IV on days -5 to -2.

  • Busulfan 82.1 mg\*hr/L IV on days -5 to -2 or days -8 to -5

  • Melphalan 50 mg/m2 IV on days -4 to -2

  • 200 mg/m2 intravenous given once on day-1

  • As seizures have occurred following high dose busulfan, all patients will be treated with Keppra beginning day -6 and continuing until day -1 per institutional guidelines.

    Also known as: Keppra

  • BiologicalAlpha/Beta T Cell-Depleted Hematopoietic Stem Cells

    Patients will be treated on the most medically appropriate regimen followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.

  • rabbit anti-thymocyte globulin (rATG). Used in conditioning regimens for in vivo depletion of T cells, and the use of fludarabine model-based dosing to optimize dosing.

    Also known as: ATG

  • Cyclophosphamide 60 mg/kg IV over 2 hours on days -3 and -2

06

What researchers measure

Primary outcomes

  1. Determine the rate of GVHD after alpha beta TCR depletion

    GVHD incidence after treatment.

    Time frame: 100 days

Secondary outcomes

  1. Transplant engraftment

    Monitor median rate of engraftment by 42 days.

    Time frame: 42 days

  2. Graft Failure

    Determine the rate of graft failure by day 100 (defined as lack of achievement of an ANC \>=500/mL with associated pancytopenia)

    Time frame: 100 days

  3. Non-relapse mortality (NRM)

    Determine the incidence of non-relapse mortality (NRM) at 100 days and 1 year

    Time frame: 12 months

  4. Overall survival (OS)

    Number of participants experiencing progression free survival at one year follow up

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • University of Minnesota Masonic Cancer Center
    Minneapolis, Minnesota 55455, United States
    Recruiting
    • Margaret MacMillan · Contact
08

References and documents

Individual participant data

Plan to share: No — For the purposes of data and safety monitoring, this study is classified as high risk (investigator initiated under an IND). Therefore the following requirements will be fulfilled: The Masonic Cancer Center Data and Safety Monitoring Council (DSMC) will review the study's progress at least quarterly. The PI will comply with at least twice yearly monitoring of the project by the Masonic Cancer Center monitoring services. The PI will oversee the submission of all reportable adverse events per the definition of reportable in Section 11.5 to the Masonic Cancer Center's SAE Coordinator, the University of Minnesota IRB, and the FDA.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Nov 2027, 54 months after the start.

Of 114 non-industry phase 2 interventional studies under Hematologic Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 95. This study's planned 54 months is close to that.

Counting every sponsor, half of 136 studies reached it within 57 months; a quarter within 40 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2023
First posted
Feb 21, 2023
StartActual
May 11, 2023
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2030
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05735717
Responsible party
Sponsor
First posted
Feb 21, 2023
Start date
May 11, 2023
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2030 (estimated)
Last update
Apr 6, 2026

Study contacts

Margaret MacMillan
Contact
macmi002@umn.edu
612-626-2961
Margaret MacMillan
principal investigator · Masonic Cancer Center, University of Minnesota

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fludarabine · Busulfan · Melphalan · Thymoglobulin · Cyclophosphamide

Start the discussion